Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||MGD013||Phase I||Actionable||In a Phase I trial, MGD013 treatment resulted in a partial response in 14.3% (2/14) and stable disease in 35.7% (5/14) of patients with triple-receptor negative breast cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD‑1 and LAG‑3, in patients with unresectable or metastatic neoplasms.||Full reference...|